A new report published by Diabetes UK, England’s leading diabetes charity, shows diabetes healthcare in England has drifted into a “state of crisis” with less than half of people with diabetes getting the basic minimum care they need.  According to the State of the Nation 2012 report there are some areas where just six...

Pfizer Inc. has announced that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline. This follows an announcement regarding the failure...

Sanofi US has announced that the iBGStar Blood Glucose Monitoring System, consisting of the iBGStar blood glucose meter and iBGStar Diabetes Manager App, is commercially available in the U.S. iBGStar is an FDA approved blood glucose meter that directly connects to the iPhone and iPod touch. iBGStar is available  for purchase at Apple...

The results of a randomized clinical trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in children with type 2 diabetes show that children and adolescents treated with a combination of metformin and Avandia (rosiglitazone) had better glycemic control than children treated with metformin alone...

The FDA has issued a complete response letter to Japanese drug-maker Takeda Pharmaceutical regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone. Recently, Takeda provided postmarketing data from outside the U.S., and has been in discussion with the FDA. The FDA has requested...

JDRF and Dexcom announced that they have formed a partnership whose goal is to accelerate the development of a novel wireless “smart transmitter” that would allow a continuous glucose monitor (CGM) system to communicate directly with an artificial pancreas control device currently being used for research studies, instead of only with...

Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine. The two studies included in total 1,635 participants and investigated insulin degludec compared to...

Kamada, announced positive preliminary interim results from a Phase I/II clinical trial of D1-AAT, which includes the Alpha 1 protein, for the treatment of type 1 diabetes. D1-AAT may slow the progression of the type 1 diabetes, and may greatly reduce or eliminate, the need for insulin. This would stabilize the condition of diabetics...

Biodel Inc. announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 — two proprietary ultra rapid acting formulations of recombinant human insulin (RHI). The objective of the trial was to identify an RHI-based formulation with pharmacokinetic and pharmacodynamic profiles...

Randy Jackson, Grammy Award-winning music producer and American Idol judge, who was diagnosed with type 2 diabetes in 2003, has partnered with Merck to help and encourage those with type 2 diabetes to live healthier lives. In a program called Taking Diabetes to Heart, Randy Jackson is using his personal experience to help others...